Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (CANF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
canf · stock forecast · 4 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$5.00
Consensus
$5.00
+62.3% upside
Low
$5.00
Median: $5 · Last Close: $3.08
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.97 | ↓ 3.61% |
1-day model range: $2.91–$3.03. Peak: $3.03 (-3.61%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CANF · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-13 | D. Boral Capital | Upgrade ↑ | Hold→Buy |
| 2026-05-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-24 | D. Boral Capital | Downgrade ↓ | Buy→Hold |
| 2025-12-17 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-18 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-09-16 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-09-02 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-07-29 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-04-15 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-03-21 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Can-Fite BioPharma Ltd. (CANF) stock. Of the recent 24 rating actions, 1 were upgrades and 2 were downgrades. 4 analysts currently cover CANF.
Analyst Recommendation Trends
CANF analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$21M
↓ 33.5% YoY
Revenue Next Year
$3M
↓ 86.3% YoY
EPS This Year
$-1.04
EPS Next Year
$-0.26
↓ 75.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast CANF EPS of $-1.04 for the current fiscal year, based on estimates from 1 analysts. The CANF revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CANF stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CANF price target is $5.00 (+62.3% upside), with an analyst consensus of Buy.
The CANF short-term stock prediction for tomorrow is $2.97 (-3.61%). The CANF stock prediction for 2030 projects a range of $1–$1.
Can-Fite BioPharma Ltd. trades on AMEX under the ticker CANF. The CANF stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
CANF forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month CANF price target is $5.00, with a high forecast of $5.00 and a low of $5.00. The median price target is shown in the chart above when available. This implies +62.3% potential upside from the current price of $3.08.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.